Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity: A Mechanistic Review.
Akash Mathavan, Akshay Mathavan, Chintan V Shah
https://pubmed.ncbi.nlm.nih.gov/41854743/Actively Recruiting
Led by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Updated on 2026-03-11
46
Participants Needed
1
Research Sites
4 weeks
Total Duration
Patients with solid tumors who receive platinum-based chemotherapy often face the risk of kidney damage caused by these drugs. This damage can lead to delays or changes in cancer treatment and worsen patient health. Currently, there are no highly effective ways to prevent this kidney injury. This study explores whether dapagliflozin, a medication known as a Sodium-Glucose Cotransporter 2 SGLT2 inhibitor, can protect the kidneys proximal tubules from this damage during chemotherapy. The trial is a randomized, double-blind, placebo-controlled Phase 2 study assessing this potential protection. Participants will be randomly assigned to receive either oral dapagliflozin 10 mg or a placebo, starting one day before their platinum-based chemotherapy and continuing for 72 hours. All patients will receive standard supportive care including hydration and magnesium supplements. The study will measure different urinary biomarkers of kidney injury, including Kidney Injury Molecule-1 KIM-1, epidermal growth factor, and others, at 72 hours and seven days after chemotherapy. Researchers will also monitor kidney function, electrolyte levels, adverse events, and cancer treatment response. Throughout the study, participants will provide urine and blood samples at specified times for biomarker and lab analysis. Kidney injury markers will be compared between the dapagliflozin and placebo groups to evaluate potential kidney protection. Safety and tolerability of dapagliflozin will be assessed during chemotherapy and up to four weeks afterward. The study aims to provide evidence that dapagliflozin may reduce kidney damage without affecting cancer treatment outcomes, with total participation lasting several weeks.
CONDITIONS
Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity
E
Erick Y Zuñiga, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 days
Participants receive oral dapagliflozin or placebo starting 24 hours before platinum-based chemotherapy and continuing for 4 days to assess kidney protection during chemotherapy.
1 baseline visit and 2 visits within 7 days after chemotherapy
Duration - Up to 4 weeks
Participants are monitored for safety, tolerability, and kidney function changes for up to 4 weeks after treatment.
Visits as needed for safety monitoring during follow-up period
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Akash Mathavan, Akshay Mathavan, Chintan V Shah
https://pubmed.ncbi.nlm.nih.gov/41854743/Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lead Sponsor